Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
A phase 2 trial of durvalumab and tremelimumab in gallbladder cancer and other biliary tract cancers, run by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, active and no longer recruiting.
Overview
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) is a phase 2, randomised interventional study registered as NCT04238637 by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, with a registry enrolment figure of 50 participants, started 2019-11-01 and due to reach its primary completion in 2026-08. Interventions recorded: Durvalumab, Tremelimumab. Conditions listed: Intrahepatic Cholangiocarcinoma. Sites: Germany. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialDurvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Shares Tremelimumab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialCombined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
Shares Tremelimumab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialStudy on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialOlaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialThe Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialPemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialDurvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialCombination Immunotherapy in Rare Cancers Under InvesTigation
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.